TriCAR19.20.22 T cells / The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) - LARVOL DELTA

Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: Ohio State University Comprehensive Cancer Center | Not yet recruiting ➔ Recruiting

Enrollment open • Acute Lymphocytic Leukemia • Chronic Lymphocytic Leukemia • Chronic Myeloid Leukemia • Hematological Malignancies • Indolent Lymphoma • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • T Acute Lymphoblastic Leukemia

Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia (clinicaltrials.gov) - P1 | N=24 | Not yet recruiting | Sponsor: Ohio State University Comprehensive Cancer Center

New P1 trial • Acute Lymphocytic Leukemia • Chronic Lymphocytic Leukemia • Chronic Myeloid Leukemia • Hematological Malignancies • Indolent Lymphoma • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • T Acute Lymphoblastic Leukemia

Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies (clinicaltrials.gov) - P1 | N=54 | Recruiting | Sponsor: Sumithira Vasu | Trial primary completion date: Apr 2025 ➔ Apr 2026

Trial primary completion date • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • B Cell Lymphoma • Chronic Lymphocytic Leukemia • Hematological Malignancies • High-grade B-cell lymphoma • Indolent Lymphoma • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Prolymphocytic Leukemia • T Acute Lymphoblastic Leukemia • CD20 • CD22

Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies (clinicaltrials.gov) - P1 | N=54 | Recruiting | Sponsor: Sumithira Vasu | N=36 ➔ 54

Enrollment change • IO biomarker • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • B Cell Lymphoma • Chronic Lymphocytic Leukemia • Hematological Malignancies • High-grade B-cell lymphoma • Indolent Lymphoma • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Prolymphocytic Leukemia • T Acute Lymphoblastic Leukemia • CD19 • CD20 • CD22

First-in-Human Phase I Study Results Presented: Trispecific CAR T-Cell Therapy (Blood Cancers Today) - P1 | N=36 | NCT05418088 | "A first-in-human phase I study has evaluated trispecific chimeric antigen receptor (CAR) T-cell therapy for targeting CD19, CD20, or CD22. This therapy is safe and viable for production, according to findings presented at the 66th American Society of Hematology Annual Meeting...For the study, successful manufacture of a trispecific CAR T-cell product was achieved for 15 of 16 patients, with a median transduction efficiency of 26%, median fold expansion of 5, and median time to manufacturing of seven days...Among 15 patients, complete response (CR) was achieved in six, two of whom by day 30 and four by day 90...Of nine patients with non-Hodgkin lymphoma (NHL), five achieved CR, three of whom have maintained CR beyond one year following treatment....Regarding safety events, cytokine release syndrome (CRS) occurred in three patients, two experiencing grade 1, one experienced grade 2, and all required tocilizumab."

Cytokine release syndrome • P1 data • B Acute Lymphoblastic Leukemia • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Prolymphocytic Leukemia • Richter's Syndrome

Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies (clinicaltrials.gov) - P1 | N=36 | Recruiting | Sponsor: Sumithira Vasu | Trial completion date: Dec 2024 ➔ Jul 2026 | Trial primary completion date: Dec 2024 ➔ Apr 2025

CAR T-Cell Therapy • IO biomarker • Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Chronic Lymphocytic Leukemia • Hematological Malignancies • Indolent Lymphoma • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Prolymphocytic Leukemia • T Acute Lymphoblastic Leukemia • CD19 • CD20 • CD22

Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies (clinicaltrials.gov) - P1 | N=36 | Recruiting | Sponsor: Sumithira Vasu | Trial primary completion date: Dec 2023 ➔ Dec 2024

CAR T-Cell Therapy • IO biomarker • Trial primary completion date • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Chronic Lymphocytic Leukemia • Hematological Malignancies • Indolent Lymphoma • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Prolymphocytic Leukemia • T Acute Lymphoblastic Leukemia • CD19 • CD20 • CD22

Federal grant helps fund CAR T-cell therapy trial for B-cell malignancies (Ohio State University) - "A five-year, $3.04 million grant from the National Cancer Institute (NCI) will help researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) study the effectiveness of a new triple-target cellular therapy they have developed to more effectively treat patients with relapsed or treatment-resistant B-cell malignancies. It will test a form of chimeric antigen receptor T-cell (CAR T-cell) therapy that targets three proteins instead of just one in patients with relapsed or treatment-resistant B-cell non-Hodgkin lymphoma, B-cell acute lymphoblastic leukemia, B-cell prolymphocytic leukemia or chronic lymphocytic leukemia....In addition to the grant from the NCI, this on-going trial is also supported by funds from the Pelotonia Idea Grant Program."

Financing • Trial status • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies (clinicaltrials.gov) - P1 | N=36 | Recruiting | Sponsor: Sumithira Vasu | Not yet recruiting ➔ Recruiting

CAR T-Cell Therapy • Enrollment open • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Chronic Lymphocytic Leukemia • Hematological Malignancies • Indolent Lymphoma • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Prolymphocytic Leukemia • T Acute Lymphoblastic Leukemia • CD20 • CD22

Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies (clinicaltrials.gov) - P1 | N=36 | Not yet recruiting | Sponsor: Sumithira Vasu

CAR T-Cell Therapy • New P1 trial • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Chronic Lymphocytic Leukemia • Hematological Malignancies • Indolent Lymphoma • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Prolymphocytic Leukemia • T Acute Lymphoblastic Leukemia • CD20 • CD22